Profile
Tracy Newbold formerly worked at United Therapeutics Corp., as Senior Director-Operations from 2011 to 2017, Atox Bio Ltd., as Senior Director-Clinical Operations from 2017 to 2020, Immunovant, Inc., as Senior Director-Clinical Operations in 2020, and Lexicon Pharmaceuticals, Inc., as Vice President-Clinical Operations.
Ms. Newbold received her undergraduate degree from The University of North Carolina at Chapel Hill.
Former positions of Tracy Newbold
| Companies | Position | End |
|---|---|---|
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Corporate Officer/Principal | 01/01/2020 |
| UNITED THERAPEUTICS CORPORATION | Chief Operating Officer | 01/01/2017 |
| LEXICON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Tracy Newbold
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
United Therapeutics Corp.
United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Provides novel immune modulators for critically ill patients with severe infections | Health Technology |
Immunovant, Inc.
Immunovant, Inc. BiotechnologyHealth Technology Develops restorative therapies for autoimmune diseases | Health Technology |
- Stock Market
- Insiders
- Tracy Newbold
















